Seq #188 Saturday, 15 March 2003
9:00 AM-11:00 AM Henry B. Gonzalez Convention Center Room 213A, Symposium - Group/Division Sponsored
Non-antimicrobial Properties of Tetracyclines: New Therapeutic Uses
* Poster files available online

Sponsored by: Microbiology / Immunology and Infection Control, Oral Medicine & Pathology, Pharmacology, Therapeutics, & Toxicology
Description: The tetracyclines have been widely used in medicine during the past 30 years due to their use as broad-spectrum antimicrobial agents. However, in the early 1980’s, research revealed that the tetracyclines had unique and unexpected properties entirely independent of their antimicrobial characteristics. These findings opened up a range of novel uses for these “old” compounds, and led to the development of a new class of pharmaceuticals with the potential to stave off the tooth loss associated with adult periodontitis, to prevent the growth and metastasis of cancer and to prevent the underlying joint breakdown in osteoarthritis and rheumatoid arthritis. Properties that have led these compounds to such a diverse array of clinical applications will be elucidated. Research evaluating concerns of potential resistance development will also be presented. By inhibiting collagen breakdown, the tetracyclines have also been shown to have an effect on the spread of cancer. Antitumor activity utilizing these compounds was recently noted in the treatment of patients with AIDS-related Kapsoi’s Sarcoma. This symposium will review the mechanisms and exciting clinical findings from these new applications for an old family of drugs. This symposium is supported by CollaGenex Pharmaceuticals, Inc
Chairpersons: R.J. CROUT and K.L. KIRKWOOD
 
  9:00 AM Chair's Opening Remarks
1497  9:05 AM Non-antimicrobial Tetracycline: Novel Drug Development
M. RYAN, SUNY at Stony Brook, NY, USA
  9:30 AM Host Modulation with Low-dose Tetracyclines for the Management of Periodontal Disease
S.G. CIANCIO, University at Buffalo, NY, USA
  9:55 AM Non-antimicrobial Tetracycline: Antibiotic Resistance Considerations
J.G. THOMAS, West Virginia University, Morgantown, USA
  10:20 AM Tetracyclines as Angiogenesis Inhibitors in the Treatment of Cancer Patients
B. DEZUBE, Harvard Medical School, Boston, MA, USA
  10:45 AM Discussion

Back to the: Symposium Program

Back to the 32nd Annual Meeting and Exhibition of the AADR (March 12-15, 2003)

Top Level Search